Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

Objectives: On the basis of the positive results of CheckMate-743, first-line (1L) treatment of malignant pleural mesothelioma (MPM) with the combination of ipilimumab and nivolumab (ipi-nivo) has become a standard-of-care. Furthermore, patients who received 1L platinum/pemetrexed chemotherapy are o...

Full description

Saved in:
Bibliographic Details
Main Authors: Sabine Schmid, MD, Lisa Holer, MSc, Katrin Gysel, MSc, Kira-Lee Koster, MD, Sacha I. Rothschild, MD, Laura A. Boos, MD, Lorenz Frehner, MD, Sabine Cardoso Almeida, MD, Christian Britschgi, MD, PhD, Yannis Metaxas, MD, Michael Mark, MD, Patrizia Froesch, MD, Wolf-Dieter Janthur, MD, Anna Allemann, MD, Christine Waibel, MD, Catherine Von der Mühll-Schill, MD, Martin Früh, MD, Laetitia A. Mauti, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:JTO Clinical and Research Reports
Subjects:
Malignant pleural mesothelioma
Ipilimumab
Nivolumab
Real-world
Outcome
Online Access:http://www.sciencedirect.com/science/article/pii/S266636432400105X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S266636432400105X

Similar Items